SCYNEXIS (SCYX) Projected to Post Earnings on Wednesday

SCYNEXIS (NASDAQ:SCYX) is expected to release its Q1 2025 earnings data before the market opens on Wednesday, May 14th. Analysts expect SCYNEXIS to post earnings of ($0.23) per share for the quarter.

SCYNEXIS (NASDAQ:SCYX) last issued its earnings results on Wednesday, March 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.13. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%. The company had revenue of $0.98 million for the quarter.

SCYNEXIS Price Performance

SCYX stock opened at $0.97 on Tuesday. SCYNEXIS has a 1-year low of $0.73 and a 1-year high of $3.07. The business has a 50 day simple moving average of $0.95 and a two-hundred day simple moving average of $1.09. The company has a market capitalization of $37.75 million, a price-to-earnings ratio of -1.31 and a beta of 1.65.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of SCYNEXIS in a research note on Thursday, May 1st. They set a “hold” rating for the company.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.